Millions of Americans can get Medicare to cover GLP-1s for weight loss starting this week. Here’s how much it costs.
1 min read
The story
Medicare officially began covering GLP-1 drugs for weight loss and obesity treatment this week, a significant policy shift from coverage that was previously limited to Type 2 diabetes, sleep apnea, and cardiovascular risk reduction. The change potentially unlocks access for tens of millions of Medicare beneficiaries who are obese but do not carry those specific diagnoses, representing a substantial new addressable market for the leading GLP-1 drugmakers.
The primary beneficiaries of this expansion are Novo Nordisk (NVO), maker of Ozempic and Wegovy, and Eli Lilly (LLY), maker of Mounjaro and Zepbound — the two dominant players in the GLP-1 space. Both companies have been racing to expand manufacturing capacity, and this policy shift could meaningfully accelerate volume growth in the U.S. market at a time when both are already managing global demand backlogs.
The bull case centers on a sudden, government-mandated demand unlock: Medicare is one of the largest payers in the country, and coverage expansion typically translates into a durable, recurring revenue stream rather than a one-time pop. However, the bear case is real — Medicare coverage comes with negotiated pricing pressure, meaning net revenue per unit could compress significantly compared to commercial insurance rates, possibly offsetting volume gains.
On the flip side, companies like Intuitive Surgical (ISRG) and bariatric-focused providers could see long-term headwinds as GLP-1 drugs increasingly substitute for surgical weight-loss interventions. Pharmacy benefit managers and insurers managing Medicare Part D formularies will also be central players in how quickly and how broadly uptake occurs.
The key variables to watch: how aggressively CMS negotiates pricing for these drugs under Part D, whether manufacturing bottlenecks at NVO and LLY constrain the actual volume benefit, and how quickly physicians begin prescribing under the expanded indication. Earnings calls from both NVO and LLY will likely be the first venue where quantified guidance on Medicare volume appears.
The case — both sides
Medicare's GLP-1 coverage expansion creates a structurally new, government-backed demand stream for LLY and NVO across tens of millions of previously unaddressed beneficiaries, which historically drives durable, multi-year volume growth when large payers add coverage of a drug class.
Medicare Part D drug price negotiation authority — now active under the Inflation Reduction Act — gives CMS significant leverage to compress net pricing on high-cost drugs like Zepbound and Wegovy, meaning expanded coverage could coincide with a meaningful reduction in per-unit revenue that offsets or exceeds the volume benefit.
The house read
Two-sidedLLY and NVO face a classic volume-vs-pricing tension as Medicare's GLP-1 expansion unlocks millions of new patients but also triggers government negotiated reimbursement rates — the question is whether the volume uplift outweighs the pricing haircut.
Wrong ifMedicare negotiated pricing under Part D could compress net realized prices for Wegovy and Zepbound sharply below commercial rates, potentially making the volume expansion margin-dilutive rather than accretive — which would undermine the bull case entirely.
Published read · research, not advice